Post ‐progression survival is highly linked to overall survival in patients with non‐small‐cell lung cancer harboring sensitive EGFR mutations treated with first‐line epidermal growth factor receptor‐tyrosine kinase inhibitors

ConclusionsPPS has a higher impact on OS than PFS in patients withEGFR‐mutated NSCLC treated with first‐line EGFR‐TKIs. These outcomes suggest that the OS in this patient group may be affected by treatments following first‐line chemotherapy; however, this remains to be verified in prospective trials.

Source: Thoracic Cancer - October 7, 2019 Category: Cancer & Oncology Authors: Hisao Imai, Kyoichi Kaira, Keita Mori, Mie Kotake, Masumi Mitani, Naoko Kawashima, Takeshi Hisada, Koichi Minato Tags: ORIGINAL ARTICLE Source Type: research